194 related articles for article (PubMed ID: 34551978)
41. Virus-like particle vaccine induces cross-protection against human metapneumovirus infections in mice.
Lévy C; Aerts L; Hamelin MÈ; Granier C; Szécsi J; Lavillette D; Boivin G; Cosset FL
Vaccine; 2013 Jun; 31(25):2778-85. PubMed ID: 23583815
[TBL] [Abstract][Full Text] [Related]
42. Structural characterization of M8C10, a neutralizing antibody targeting a highly conserved prefusion-specific epitope on the metapneumovirus fusion trimerization interface.
Xiao X; Wen Z; Chen Q; Shipman JM; Kostas J; Reid JC; Warren C; Tang A; Luo B; O'Donnell G; Fridman A; Chen Z; Vora KA; Zhang L; Su H-P; Eddins MJ
J Virol; 2023 Dec; 97(12):e0105223. PubMed ID: 38032197
[TBL] [Abstract][Full Text] [Related]
43. Design and characterization of a fusion glycoprotein vaccine for Respiratory Syncytial Virus with improved stability.
Zhang L; Durr E; Galli JD; Cosmi S; Cejas PJ; Luo B; Touch S; Parmet P; Fridman A; Espeseth AS; Bett AJ
Vaccine; 2018 Dec; 36(52):8119-8130. PubMed ID: 30340881
[TBL] [Abstract][Full Text] [Related]
44. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
[TBL] [Abstract][Full Text] [Related]
45. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes.
McLellan JS; Yang Y; Graham BS; Kwong PD
J Virol; 2011 Aug; 85(15):7788-96. PubMed ID: 21613394
[TBL] [Abstract][Full Text] [Related]
46. Characterization of potent RSV neutralizing antibodies isolated from human memory B cells and identification of diverse RSV/hMPV cross-neutralizing epitopes.
Xiao X; Tang A; Cox KS; Wen Z; Callahan C; Sullivan NL; Nahas DD; Cosmi S; Galli JD; Minnier M; Verma D; Babaoglu K; Su H; Bett AJ; Vora KA; Chen Z; Zhang L
MAbs; 2019; 11(8):1415-1427. PubMed ID: 31402751
[TBL] [Abstract][Full Text] [Related]
47. An alphavirus replicon-based human metapneumovirus vaccine is immunogenic and protective in mice and cotton rats.
Mok H; Tollefson SJ; Podsiad AB; Shepherd BE; Polosukhin VV; Johnston RE; Williams JV; Crowe JE
J Virol; 2008 Nov; 82(22):11410-8. PubMed ID: 18786987
[TBL] [Abstract][Full Text] [Related]
48. SOS and IP Modifications Predominantly Affect the Yield but Not Other Properties of SOSIP.664 HIV-1 Env Glycoprotein Trimers.
Ringe RP; Colin P; Torres JL; Yasmeen A; Lee WH; Cupo A; Ward AB; Klasse PJ; Moore JP
J Virol; 2019 Dec; 94(1):. PubMed ID: 31619555
[TBL] [Abstract][Full Text] [Related]
49. Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers.
Schorcht A; van den Kerkhof TLGM; Cottrell CA; Allen JD; Torres JL; Behrens AJ; Schermer EE; Burger JA; de Taeye SW; Torrents de la Peña A; Bontjer I; Gumbs S; Ozorowski G; LaBranche CC; de Val N; Yasmeen A; Klasse PJ; Montefiori DC; Moore JP; Schuitemaker H; Crispin M; van Gils MJ; Ward AB; Sanders RW
J Virol; 2020 Nov; 94(24):. PubMed ID: 32999024
[TBL] [Abstract][Full Text] [Related]
50. Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses.
Mukhamedova M; Wrapp D; Shen CH; Gilman MSA; Ruckwardt TJ; Schramm CA; Ault L; Chang L; Derrien-Colemyn A; Lucas SAM; Ransier A; Darko S; Phung E; Wang L; Zhang Y; Rush SA; Madan B; Stewart-Jones GBE; Costner PJ; Holman LA; Hickman SP; Berkowitz NM; Doria-Rose NA; Morabito KM; DeKosky BJ; Gaudinski MR; Chen GL; Crank MC; Misasi J; Sullivan NJ; Douek DC; Kwong PD; Graham BS; McLellan JS; Mascola JR
Immunity; 2021 Apr; 54(4):769-780.e6. PubMed ID: 33823129
[TBL] [Abstract][Full Text] [Related]
51. Individual contributions of the human metapneumovirus F, G, and SH surface glycoproteins to the induction of neutralizing antibodies and protective immunity.
Skiadopoulos MH; Biacchesi S; Buchholz UJ; Amaro-Carambot E; Surman SR; Collins PL; Murphy BR
Virology; 2006 Feb; 345(2):492-501. PubMed ID: 16300813
[TBL] [Abstract][Full Text] [Related]
52. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody.
Corti D; Bianchi S; Vanzetta F; Minola A; Perez L; Agatic G; Guarino B; Silacci C; Marcandalli J; Marsland BJ; Piralla A; Percivalle E; Sallusto F; Baldanti F; Lanzavecchia A
Nature; 2013 Sep; 501(7467):439-43. PubMed ID: 23955151
[TBL] [Abstract][Full Text] [Related]
53. Chimeric
Olmedillas E; Cano O; Martínez I; Luque D; Terrón MC; McLellan JS; Melero JA; Más V
EMBO Mol Med; 2018 Feb; 10(2):175-187. PubMed ID: 29217660
[TBL] [Abstract][Full Text] [Related]
54. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
[TBL] [Abstract][Full Text] [Related]
55. Human metapneumovirus fusion protein vaccines that are immunogenic and protective in cotton rats.
Cseke G; Wright DW; Tollefson SJ; Johnson JE; Crowe JE; Williams JV
J Virol; 2007 Jan; 81(2):698-707. PubMed ID: 17050599
[TBL] [Abstract][Full Text] [Related]
56. Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.
Liang B; Ngwuta JO; Surman S; Kabatova B; Liu X; Lingemann M; Liu X; Yang L; Herbert R; Swerczek J; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Collins PL; Munir S
J Virol; 2017 Aug; 91(15):. PubMed ID: 28539444
[TBL] [Abstract][Full Text] [Related]
57. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
Patel N; Massare MJ; Tian JH; Guebre-Xabier M; Lu H; Zhou H; Maynard E; Scott D; Ellingsworth L; Glenn G; Smith G
Vaccine; 2019 Sep; 37(41):6112-6124. PubMed ID: 31416644
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of pre- and post-fusion Human metapneumovirus F proteins as subunit vaccine candidates in mice.
Pilaev M; Shen Y; Carbonneau J; Venable MC; Rhéaume C; Lavigne S; Couture C; Guarné A; Hamelin MÈ; Boivin G
Vaccine; 2020 Feb; 38(9):2122-2127. PubMed ID: 32007293
[TBL] [Abstract][Full Text] [Related]
59. Antibodies from Rabbits Immunized with HIV-1 Clade B SOSIP Trimers Can Neutralize Multiple Clade B Viruses by Destabilizing the Envelope Glycoprotein.
van Haaren MM; McCoy LE; Torres JL; Lee W; Cottrell CA; Copps JL; van der Woude P; Yasmeen A; de Taeye SW; Torrents de la Peña A; Moore JP; Burton DR; Klasse PJ; Ward AB; Sanders RW; van Gils MJ
J Virol; 2021 Aug; 95(17):e0009421. PubMed ID: 34076487
[TBL] [Abstract][Full Text] [Related]
60. A Sendai virus recombinant vaccine expressing a gene for truncated human metapneumovirus (hMPV) fusion protein protects cotton rats from hMPV challenge.
Russell CJ; Jones BG; Sealy RE; Surman SL; Mason JN; Hayden RT; Tripp RA; Takimoto T; Hurwitz JL
Virology; 2017 Sep; 509():60-66. PubMed ID: 28605636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]